Anakinra for the treatment of rheumatoid arthritis: a safety evaluation

Expert Opin Drug Saf. 2018 Jul;17(7):727-732. doi: 10.1080/14740338.2018.1486819. Epub 2018 Jun 14.

Abstract

The anti-interleukin-1 receptor antagonist, anakinra, was approved for the treatment of rheumatoid arthritis (RA) more than 12 years ago. However, its adverse effects are not well known. Areas covered: We review the safety profile of anakinra, analyzing clinical trials, observational studies, and registry data. Expert opinion: Due to its lower efficacy compared with other biological therapies approved for RA and its daily subcutaneous administration, anakinra is used only marginally for the treatment of RA. This has limited the experience with this drug in RA, with a lack of data from long-term observational studies or registries. From the five clinical trials performed, and given the unfeasibility of developing new studies of anakinra in RA, it may be concluded that site injection reactions, infections at higher doses (>100 mg), and immunogenicity are the most frequent adverse events related to anakinra administration.

Keywords: Anakinra; clinical trial; review; rheumatoid arthritis; safety.

Publication types

  • Review

MeSH terms

  • Antirheumatic Agents / administration & dosage
  • Antirheumatic Agents / adverse effects*
  • Arthritis, Rheumatoid / drug therapy*
  • Arthritis, Rheumatoid / immunology
  • Humans
  • Interleukin 1 Receptor Antagonist Protein / administration & dosage
  • Interleukin 1 Receptor Antagonist Protein / adverse effects*
  • Receptors, Interleukin-1 / antagonists & inhibitors

Substances

  • Antirheumatic Agents
  • Interleukin 1 Receptor Antagonist Protein
  • Receptors, Interleukin-1